Group 1: Company Performance and Market Opportunities - The company reported significant growth in the sanitary napkin segment, with a market size in China exceeding 100 billion RMB, indicating vast growth potential despite being a relatively small player [5] - The aging population and increasing health management needs are driving demand for medical supplies, creating a larger market space for the company [2] - The company aims to enhance its market competitiveness by focusing on disposable medical supplies through acquisitions and expanding its product categories [2] Group 2: Strategic Initiatives - The company is committed to providing integrated solutions for hospitals, pharmacies, and home care, addressing pain points in quality, supply chain, and digital integration [2] - Continuous investment in R&D is prioritized to innovate products that fill market gaps and meet patient and healthcare institution needs [2] - The company is advancing smart manufacturing and AI technology applications to improve production efficiency and reduce costs [2] Group 3: Channel Strategy and Growth Projections - The medical segment's channel strategy includes overseas business, domestic hospital lines, consumer medical business, and cross-border e-commerce, with a focus on significant growth in domestic hospital lines in 2025 [9][10] - The overseas business is primarily focused on Europe, while the domestic hospital segment is being segmented into traditional dressings, surgical materials, and high-end dressings [9] - The cross-border e-commerce channel has been the fastest-growing, particularly on platforms like Amazon, despite potential impacts from current tariff policies [10] Group 4: Impact of Tariff Policies - The company anticipates limited impact from U.S. tariff policies, with affected sales in overseas divisions and cross-border e-commerce remaining in single-digit percentages of the medical segment [6][7] - Strategies to mitigate tariff impacts include increasing investments in South America and expanding existing U.S. operations [6][7] - The company maintains strong competitive advantages in the U.S. market for medical supplies, with various strategies to manage tariff-related challenges [7] Group 5: Brand Management and Investor Relations - The company has implemented a market value management system to protect and return value to investors, with regular monitoring against industry benchmarks [11] - A rising trend in dividend payouts has been established, with plans for mid-year dividends starting in 2024 [11] - The company emphasizes transparency and communication with investors, enhancing information disclosure and hosting performance briefings [11] Group 6: Product Development and Consumer Engagement - The company is focusing on product innovation in the sanitary napkin sector, utilizing high-quality cotton and advanced technologies to enhance user experience [5] - Initiatives to improve consumer trust include product traceability through QR codes and real-time factory monitoring [14][15] - The company is actively engaging with consumers for feedback on product improvements, integrating suggestions into new product developments [14]

2025 年 05 月 05 日 投资评级：买入（维持） | 日期 | 2025/4/30 | | --- | --- | | 当前股价(元) | 52.22 | | 一年最高最低(元) | 54.80/23.31 | | 总市值(亿元) | 304.09 | | 流通市值(亿元) | 91.65 | | 总股本(亿股) | 5.82 | | 流通股本(亿股) | 1.76 | | 近 3 个月换手率(%) | 204.85 | 股价走势图 美容护理/个护用品 2025Q1 净利润高增，消费品业务延续强劲品牌势能 数据来源：聚源 -30% 0% 30% 60% 90% 2024-05 2024-09 2025-01 稳健医疗 沪深300 相关研究报告 《Q3 收入提速重启增长道路，股权激 励彰显信心—公司信息更新报告》 -2024.10.31 《收购 GRI 协同赋能，打造全球耗材 一站式解决方案—公司信息更新报 告》-2024.9.26 《消费高质量增长&医疗恢复增长，看 好新元年向上—公司信息更新报告》 -2024.8.30 | | | ——公司信息更新报告 | | --- | --- | --- | | ...

美容护理/个护用品 2025Q1 净利润高增，消费品业务延续强劲品牌势能 2025 年 05 月 05 日 投资评级：买入（维持） | 日期 | 2025/4/30 | | --- | --- | | 当前股价(元) | 52.22 | | 一年最高最低(元) | 54.80/23.31 | | 总市值(亿元) | 304.09 | | 流通市值(亿元) | 91.65 | | 总股本(亿股) | 5.82 | | 流通股本(亿股) | 1.76 | | 近 3 个月换手率(%) | 204.85 | 股价走势图 数据来源：聚源 -30% 0% 30% 60% 90% 2024-05 2024-09 2025-01 稳健医疗 沪深300 相关研究报告 《Q3 收入提速重启增长道路，股权激 励彰显信心—公司信息更新报告》 -2024.10.31 《收购 GRI 协同赋能，打造全球耗材 一站式解决方案—公司信息更新报 告》-2024.9.26 《消费高质量增长&医疗恢复增长，看 好新元年向上—公司信息更新报告》 -2024.8.30 | | | ——公司信息更新报告 | | --- | --- | --- | | ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [6][14]. Core Insights - The company reported a revenue of 8.978 billion RMB for 2024, representing a year-on-year growth of 9.69%, and a net profit of 695 million RMB, up 19.81% [2]. - For Q1 2025, the company achieved a revenue of 2.605 billion RMB, a significant increase of 36.47%, with a net profit of 249 million RMB, also up 36.26% [2]. - The company is expected to benefit from dual growth drivers in the consumer goods and medical sectors [2]. Performance Analysis - The consumer goods segment showed strong growth, with Q4 2024 revenue reaching 2.908 billion RMB, a 33.72% increase [3]. - For 2024, the medical supplies and consumer goods segments generated revenues of 3.906 billion RMB and 4.991 billion RMB, growing by 1.14% and 17.09% respectively [3]. - Key product categories such as cotton soft towels and children's clothing saw revenue increases of 31.19% and 13.21% respectively [3]. Q1 2025 Development - In Q1 2025, the medical segment generated 1.25 billion RMB, a 46.3% increase, with core categories like surgical supplies and high-end dressings showing remarkable growth [4]. - The consumer segment achieved 1.34 billion RMB in revenue, up 28.8%, with the "Princess Nais" sanitary napkin leading the category with a 73.5% increase [4]. - E-commerce contributed 59.9% of total revenue, with rapid growth in supermarket channels, which saw a 70.9% year-on-year increase [4]. Profitability - The gross margin for 2024 and Q1 2025 was 48.46% and 47.32% respectively, with a slight improvement in Q1 2025 due to product mix optimization [5]. - The net profit margin remained stable at 7.75% for 2024 and improved to 9.54% in Q1 2025 [5]. - The company aims to enhance brand strength and operational efficiency while focusing on core product categories [5]. Earnings Forecast and Valuation - The company is projected to have EPS of 1.80, 2.12, and 2.54 RMB for 2025, 2026, and 2027 respectively, with corresponding PE ratios of 27, 23, and 19 [6].